Markets:

Overview

News

Currencies

International

Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

25.07 +1.19 (+4.98%)

Streaming Delayed Price Updated: 1:57 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Syndax (SNDX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Syndax (SNDX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q4 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗

February 26, 2026

Via Chartmill

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Syndax Pharmaceuticals's Earnings Outlook ↗

October 31, 2025

Via Benzinga

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval ↗

October 24, 2025

Via Stocktwits

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

Why Is Syndax Stock Down Today? ↗

October 24, 2025

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) are trading lower Friday following approval of one of its treatments from the U.S.'s Food and Drug Administration.

Via Benzinga

Where Syndax Pharmaceuticals Stands With Analysts ↗

October 16, 2025

Via Benzinga

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗

September 04, 2025

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.

Via Benzinga

This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

September 04, 2025

Via Benzinga

Syndax Pharmaceuticals's Earnings: A Preview ↗

August 01, 2025

Via Benzinga

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Syndax Pharmaceuticals's Earnings: A Preview ↗

November 04, 2024

Via Benzinga

Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗

September 04, 2025

Via Benzinga

Syndax (SNDX) Q2 Revenue Jumps 986% ↗

August 04, 2025

Via The Motley Fool

Topics Intellectual Property

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower EPS Loss ↗

August 04, 2025

Syndax Pharmaceuticals reported mixed Q2 2025 results, beating revenue estimates with $37.96M but posting an EPS loss of ($0.83). Revuforj sales surged 43%, while shares dipped 3.66% post-earnings.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

May 20, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Via Chartmill

Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday ↗

May 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 06, 2025

Via Benzinga

NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 29, 2025

Via Benzinga

Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

April 29, 2025

Via Benzinga

Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth ↗

March 21, 2025

JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.

Via Benzinga

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks ↗

January 17, 2025

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns.

Via Investor's Business Daily

Topics Government

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday ↗

November 18, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 12, 2024

Via Benzinga

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer ↗

November 12, 2024

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.